PHASE II TRIAL OF ANTI-PD1 THERAPY FOR HPV-ASSOCIATED RECURRENT RESPIRATORY PAPILLOMATOSIS (IND#128874)
Federal financial assistance recorded from USAspending. This is not a procurement contract.
Research this with AI
Research smarter with AI
Analyze opportunities and compare insights across leading AI models.
ASST_NON_R01FD006341_075 · THE GENERAL HOSPITAL CORPORATION · Department of Health and Human Services
Compare Multiple AI Models with SmartSoloExplore CaptureIQ IntelligenceAssistance award details
- Assistance award identifier
- ASST_NON_R01FD006341_075
- FAIN
- R01FD006341
- Recipient
- THE GENERAL HOSPITAL CORPORATION
- Awarding agency
- Department of Health and Human Services
- Funding agency
- Department of Health and Human Services
- Assistance listing (CFDA)
- 93.103
- Total obligated
- $1,045,538
- Period
- Sep 1, 2019 – Aug 31, 2022
- Fiscal year
- 2019
- Place of performance state
- MA
- Source file
- FY2019_All_Assistance_Full_20261006.zip
Description
PHASE II TRIAL OF ANTI-PD1 THERAPY FOR HPV-ASSOCIATED RECURRENT RESPIRATORY PAPILLOMATOSIS (IND#128874)